BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
May 31, 2025 β’ 15min
ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline
He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite.
May 30, 2025 β’ 10min
ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news
He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for their asset to date. Plus, plans for future data later this year and getting a U.S. study up and running.
May 30, 2025 β’ 19min
Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry
Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation.
May 29, 2025 β’ 7min
Piper Sandler Senior Analyst David Amsellem reacts to today's Teva Innovation & Strategy Day and shares his take on the company's pipeline
He gives his thoughts on the competitiveness of Teva's TL1A, and highlights other pipeline programs that biotech investors might look at. Plus, how the company is doing transitioning its investor base from generic drug focused investors to biotech.
May 29, 2025 β’ 8min
At Teva's Innovation & Strategy Day in New York today, CEO Richard Francis discusses what 'Pivot to Growth' means for the company and offers takeaways from the presentation
He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech investors have been watching closely.
May 28, 2025 β’ 16min
Previewing top breast cancer and antibody-drug conjugate presentations to watch at this week's ASCO Annual Meeting with Dana-Farber's Paolo Tarantino
He describes key presentations for Enhertu, TRODELVY, immunotherapy medicines, and a couple key biomarkers to watch.
May 21, 2025 β’ 6min
RBC Global Healthcare Conference: Desk Strategist Chris McCarthy shares how institutional investors have been affected by policy and macro factors, and how they have been positioning around catalysts
He describes how policy, macro, and events have been affecting trading in biotech stocks lately. Plus, his thoughts on the pull back of generalists from the sector.
May 21, 2025 β’ 9min
RBC Global Healthcare Conference: Senior Biotech Analyst Luca Issi shares his thoughts on the current state of gene and cell therapy
He shares his overall thoughts on the biotech market, and discusses gene therapies, RNA editing, and cell therapy.
May 21, 2025 β’ 10min
RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year
CEO Ram Aiyar describes Korro's 'OPERA' platform and explains why he thinks it is differentiated from others in the field. He previews the first data announcement that will happen later this year and discusses other work, including with the company's partner Novo Nordisk.
May 21, 2025 β’ 12min
RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead
CEO Sanjay Shukla describes the science behind tRNA synthetase biology and how aTyr is leveraging it against inflammatory and fibrotic diseases, especially pulmonary disease. He sets up the phase 3 for Efzofitimod in pulmonary sarcoidosis, and also pending data in systemic sclerosis.
